Trial Profile
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study of Pembrolizumab (MK-3475) in Combination With Epacadostat or Placebo in Subjects With Unresectable or Metastatic Melanoma (Keynote-252 / ECHO-301)
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 12 May 2022
Price :
$35
*
At a glance
- Drugs Epacadostat (Primary) ; Pembrolizumab (Primary)
- Indications Malignant melanoma
- Focus Registrational; Therapeutic Use
- Acronyms Keynote-252 / ECHO-301
- Sponsors Incyte Corporation; Merck Sharp & Dohme
- 27 Oct 2020 This trial has been completed in Netherlands, according to European Clinical Trials Database.
- 20 Jul 2020 This trial has been completed in United Kingdom, according to European Clinical Trials Database.
- 24 Dec 2019 This trial has been completed in Sweden, according to European Clinical Trials Database.